Goldman Sachs analyst Geydar Mamedov downgrades BHP Group (NYSE:BHP) from Buy to Neutral.
BMO Capital Upgrades Beam Therapeutics to Outperform, Raises Price Target to $66
BMO Capital analyst Kostas Biliouris upgrades Beam Therapeutics (NASDAQ:BEAM) from Market Perform to Outperform and raises the price target from $61 to $66.